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In patients with symptomatic multiple myeloma (MM), bisphos-
phonate (BP) treatment has been widely used to prevent
bone loss and preserve skeletal health because of its proven
effects on inhibiting osteoclast-mediated bone resorption. In
addition to their effects on osteoclasts, it is becoming
increasingly evident that BPs may have additional effects on
the bone microenvironment and cells other than osteoclasts
that may potentially inhibit the development and progression of
MM. This review focuses on the pathophysiology of MM with an
emphasis on the events that drive MM progression within the
bone and the mechanisms by which BPs may inhibit speciﬁc
processes. The underlying molecular mechanisms that drive
the modulation of cellular fate and function and consequent
physiological outcomes are described. Direct effects on
myeloma cell growth and survival and the interactions between
myeloma cells and the bone microenvironment are discussed.
Clinical evidence of the antimyeloma effects of BPs is emerging
and is also reviewed.
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Introduction
Monoclonal gammopathy of unknown signiﬁcance is an asymp-
tomatic condition characterized by the clonal expansion of
plasma cells. In a small proportion of patients, monoclonal
gammopathy of unknown signiﬁcance progresses through a
multistage process to symptomatic and malignant multiple
myeloma (MM). There are few somatic genetic differences
between the asymptomatic monoclonal gammopathy of unknown
signiﬁcance and malignant MM.
1 Interactions between myeloma
cells and bone cells and the extracellular matrix proteins within
the bone microenvironment underlie this progression and are
mediated through cell surface receptorsFfor example, integrins,
cadherins, selectins, syndecans and the immunoglobulin super-
family of cell adhesion molecules.
2 These interactions trigger a
self-amplifying cascade of events that result in the secretion of
cytokines and growth factors (such as vascular endothelial growth
factor (VEGF), insulin-like growth factor-1, interleukin-6 (IL-6) and
IL-1b)a n dm e m b e r so ft h et u m o rn e c r o s i sf a c t o rs u p e r f a m i l y
(TGFb1, CCL3, hepatocyte growth factor and IL-10) that promote
the growth and proliferation of myeloma cells, increase bone
resorption and enhance drug resistance by inducing antiapoptotic
pathways.
1,2 The underlying mechanisms and pathways driving
this vicious cycle of tumor growth and bone destruction have
been extensively reviewed.
1,3–5
Bisphosphonates (BPs) are degradation-resistant analogs
of inorganic pyrophosphate that can inhibit bone resorption.
This effect is of particular clinical relevance in patients with
symptomatic MM who, as a consequence of the physiological
changes induced by malignant bone disease, undergo profound
bone loss. Newer generation, nitrogen-containing BPs (N-BPs)
prevent bone loss because of cellular effects involving both
apoptosis of the osteoclasts and the destruction of the
osteoclastic cytoskeleton, resulting in decreased osteoclast
activity. The biochemical basis of these effects for N-BPs (for
example, alendronate, risedronate, ibandronate, pamidronate
and zoledronic acid) is the inhibition of farnesyl pyrophosphate
synthase (FPPS), a key branch-point enzyme in the mevalonate
pathway.
6,7 Consequently, cellular availability of isoprenoid
lipids such as farnesyl pyrophosphate and geranylgeranyl
pyrophosphate is decreased and the post-translational modiﬁca-
tion and function of small GTP-binding proteins that modulate
key signaling events involved in cell survival, differentiation and
proliferation are impaired.
8–10 Experiments in several in-vitro
and in-vivo experimental model systems of cancer in general
and MM in particular suggest that BPs may negatively modulate
promyeloma signaling events and thereby provide clinical
beneﬁts that extend beyond bone conservation. This review
examines the mechanisms by which BPs may interfere with
progression of MM.
Preclinical evidence and molecular basis of antimyeloma
effects of BPs
Several preclinical studies have provided strong evidence for
the antimyeloma potential of BPs (Figure 1).
2,11–18 In a study
by Baulch-Brown et al,
19 the authors showed that myeloma cells
treated with zoledronic acid, or other mevalonate pathway
antagonists such as ﬂuvastatin (an HMG-CoA reductase
inhibitor) or SCH66336 (a farnesyl transferase inhibitor)
suppressed the proliferation of myeloma cells (RPMI 8226,
U266, OMP2, LP1 and NCI-H929) and that combinations
of zoledronic acid and ﬂuvastatin, but not zoledronic acid and
SCH66336 acted synergistically. The study also showed that the
antiproliferative effect of mevalonate pathway inhibitors is
mediated principally by prevention of geranylgeranylation and
is the result of both cell-cycle arrest and apoptosis induction.
Indeed, microarray and quantitative real-time PCR analyses
further demonstrated that genes related to apoptosis, cell-cycle
control and the mevalonate pathway were particularly affected
by zoledronic acid and ﬂuvastatin, and that some of these
transcriptional effects were synergistic. Similarly, incadronate
and mevastatin (a known inhibitor of the mevalonate pathway)
caused apoptosis in JJN-3 myeloma cells and inhibited cell
proliferation.
20 Moreover, mevalonate pathway intermediates
such as geranylgeraniol and farnesol prevented incadronate-
induced apoptosis of JJN-3 myeloma cells and had a partial
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of incadronate are a direct consequence of its known mecha-
nism of action (that is, mevalonate pathway inhibition).
In a study by Shipman et al
21 in the human myeloma cell line
JJN-3 and the EBV transformed Burkitt lymphoma cell line
HS-Sultan,
22 pamidronate and the more potent BP, YM175,
induced apoptosis and signiﬁcantly decreased cell number
(Po0.001). Both pamidronate and YM175 increased in the
proportion of cells with altered nuclear morphology (Po0.05)
and fragmented DNA, in both JJN-3 and HS-Sultan cells.
In contrast, clodronate, a BP that does not contain any nitrogen
and does not inhibit the mevalonate pathway, had little effect on
cell number and did not cause apoptosis at the concentrations
examined. In another study, risedronate dose dependently
inhibited prenylation of (ras in brain) RAB GTPases (for example,
Rap1A and Rab6), eliciting a dose-dependent apoptotic response
in human myeloma cells and arresting these cells in the S
phase.
23 This study also showed that geranylgeraniol prevented
inhibition of prenylation, induction of apoptosis and cell-cycle
arrest in response to risedronate. These data support the critical
role of mevalonate pathway inhibition by N-BPs and the
consequent impairment of function of small GTPases
in mediating the observed anticancer effects (Figure 1a).
The role of isoprenylation of proteins in mediating these
events is also supported by data from a more recent study in
the 5T2MM model of MM that showed that 3-PEHPC (2-[3-
pyridinyl]-1-hydroxyethylidene-1,1-phosphonocarboxylic acid),
a novel geranylgeranyl-transferase II inhibitor, prevented bone
loss, inhibited the development of osteolytic bone lesions and
reduced myeloma burden in bone.
24 In contrast to other agents
that inhibit the mevalonate pathway or post-translational
prenylation, BPs have a natural afﬁnity toward bone mineral
that limits the effects of mevalonate pathway inhibition to select
cellular components (mainly osteoclasts, and non-osteoclast
cells including tumor cells and lymphocytes) within the bone
microenvironment. This is particularly desirable in a disease
such as MM, a disease whose progression is primarily driven
within the bone.
In addition to data from cell-culture experiments, in-vivo
experiments in animal models of MM provide additional
evidence of the antimyeloma activity of BPs. For example,
zoledronic acid signiﬁcantly prolonged survival in severe
combined immunodeﬁciency mice inoculated with human
INA-6 plasma cells.
12 Importantly, this study used clinically
relevant doses of zoledronic acid, and histological analysis
of INA-6 tumors from the peritoneal cavity revealed extensive
areas of apoptosis associated with poly (ADP ribose) poly-
merase cleavage. Furthermore, western blot analysis of tumor
homogenates demonstrated the accumulation of unprenylated
Rap1A, which is indicative of the uptake of zoledronic acid
by non-skeletal tumors and inhibition of the mevalonate
pathway.
Figure 1 N-BPs may modulate myeloma progression through their effects on the mevalonate pathway and directly on MM plasma cells, bone
marrow cells and immune cells in the bone marrow. (a) N-BPs affect cell survival by blocking the key enzyme (that is, FPPS) in the mevalonate
pathway required for prenylation of proteins.
11,12,14 (b) N-BPs prevent proliferation of MM plasma cells directly via inhibition of growth factors
that promote cell growth and survival within the bone microenvironment and indirectly via inhibition of angiogenesis (left).
2,14–18 N-BPs enhance
host antitumor immune response (right).
13 The dotted line depicts the boundary between the bone microenvironment and the extraskeletal
vasculature. bFGF, ﬁbroblast growth factor; FPPS, farnesyl pyrophosphate synthase; HGF, hepatocyte growth factor; IGF-1, insulin-like growth
factor-1; N-BP, nitrogen-containing bisphosphonate/aminobisphosphonate; NF-kB, nuclear factor-kB; PDGF, platelet-derived growth factor;
TNF-a, tumor necrosis factor-a.
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LeukemiaSimilarly, in another in-vivo study, zoledronic acid prevented
the formation of skeletal lesions, prevented cancellous bone loss
and loss of bone mineral density, and reduced osteoclast
perimeter in mice injected with 5T2MM murine myeloma
cells.
25 Zoledronic acid also decreased paraprotein concen-
tration, decreased tumor burden and reduced angiogenesis.
In separate experiments, Kaplan–Meier analysis demonstrated a
signiﬁcant increase in disease-free survival after treatment with
zoledronic acid when compared with control (Po0.005). Thus,
these data are consistent with the antimyeloma effects observed
with other mevalonate pathway inhibitors.
As a consequence of the inhibition of the mevalonate
pathway in cells, N-BPs can induce formation of a novel ATP
analog, triphosphoric acid 1-adenosin-50-yl ester 3-(3-methyl-
but-3-enyl) ester or ApppI.
26 Accumulation of ApppI correlated
with the capacity of N-BPs to inhibit the mevalonate pathway in
macrophages. ApppI inhibited the mitochondrial ADP/ATP
translocase in isolated rat liver mitochondria and caused
apoptosis in osteoclasts. These data broaden the mechanistic
basis of N-BPs’ action (beyond inhibition of post-translational
modiﬁcation of small GTPases involved in cell signaling) to
include ApppI formation. In contrast to mevalonate pathway
inhibition that results in impaired function of small GTPases,
ApppI functions through the blockade of mitochondrial
ADP/ATP translocase, thereby inducing apoptosis. In addition
to its effects on mitochondrial function, ApppI and another
intermediate, isopentenyl pyrophosphate (IPP), are phospho-
antigens that can enhance host anticancer activity.
Raikkonen et al
27 reported that zoledronic acid-induced
IPP/ApppI accumulation in MCF-7 breast cancer cells was
decreased by farnesol and almost completely blocked by
geranylgeraniol and geranyl pyrophosphate. The functionality
of the regulatory enzymes of IPP and ApppI, IPP isomerase and
aminoacyl-tRNA synthase, respectively, or protein levels of
FPPS were not affected by the treatments. However, protein
levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(the rate-controlling enzyme of the mevalonate pathway) and
unprenylated Rap1A were decreased, thereby suggesting that
mevalonate pathway intermediates may also rescue N-BP effects
by inhibiting IPP/ApppI accumulation.
27 Thus, the anticancer
effects of mevalonate pathway inhibition result from multiple
outcomes including impairment of function of small GTPases,
inhibition of ATP/ADP translocase and stimulation of host
antitumor activity.
Synergistic activity of BPs with other agents and
antimyeloma therapies
Sequential blockage of the mevalonate pathway by zoledronic
acid and simvastatin resulted in the synergistic induction of
apoptosis and reversal of cell adhesion-mediated drug resis-
tance.
28 Treatment of myeloma cell lines with the combination
of zoledronic acid and dexamethasone also demonstrated
synergistic induction of apoptosis in vitro, providing a rationale
for potential applications in vivo.
29,30 In another study,
bortezomib and zoledronic acid showed distinct and synergistic
inhibitory effects on cell proliferation, adhesion, migration and
expression of angiogenic cytokines (for example, VEGF, bFGF,
hepatocyte growth factor and platelet-derived growth factor).
14
Similar effects were observed on capillarogenic organization
and expression of vascular markers in cells that became
vasculogenic. Activation of VEGFR2, ERK1/2 and NF-kB activity
was also inhibited. Overall, these data provide evidence that the
exposure of bone marrow macrophages in MM during treatment
with zoledronic acid impacts their angiogenic and vasculogenic
properties (Figure 1b).
BPs as immunomodulators
In addition to their direct effects on cancer and bone cells,
BPs may also repress cancer progression by stimulating the host
anticancer response and/or by inhibiting proangiogenic signal-
ing by immune cells. Newer generation BPs appear to induce or
activate Vg9Vd2 subset T cells by mimicking phosphoantigens
and/or by increasing circulating phosphoantigen levels.
31
The Vg9Vd2 T cells have antitumor activity and appropriate
cell surface antigens to target secondary lymphoid organs and
exert costimulatory activity.
32 BP treatment has been shown to
induce the accumulation of IPP and dimethylallyl bisphos-
phonate, phosphoantigens that activate Vg9Vd2 T cells.
13
Several studies have demonstrated that zoledronic acid treat-
ment causes the expansion of Vg9Vd2 T-cell populations and
increases sensitivity of cancer cells to the cytotoxic effects of
Vg9Vd2 T cells.
33,34 In a small clinical study, patients infused
with zoledronic acid-activated Vg9Vd2 T cells generated from
the culture of peripheral blood mononuclear cells maintained
their M-protein levels in the serum at baseline, demonstrating
that activation of the innate host antitumor response by N-BPs
can successfully control the expansion of myeloma cells.
35
In MM, cells belonging to the monocyte-macrophage lineage
form part of an inﬂammatory circuit that promotes tumor
progression, invasion and metastasis mainly through their
proangiogenic activity.
16,18 These cells express a broad array
of matrix metalloproteases, proangiogenic cytokines and growth
factors. The combination of factors facilitates matrix breakdown
and tunneling that promote neovascularization and invasion.
A recent study evaluating the effect of clinically relevant doses
of zoledronic acid on bone metastasis in a constitutionally
active ErbB-2 transgenic mouse model reported that zoledronic
acid treatment resulted in M2 (anti-inﬂammatory and proangio-
genic) to M1 (antitumor) reversion of tumor-associated
macrophages.
36 This study also reported that zoledronic acid
treatment resulted in a profound reduction in CD11
þ macro-
phages inﬁltrating mammary lesions and was accompanied by
reduced vascularization of the tumor and decreased VEGF
levels in the tumor microenvironment. Moreover, this study
also showed that Ras prenylation and Ras-GTP levels were
suppressed by treatment with zoledronic acid. Overall, the
study demonstrated that zoledronic acid improved disease-free
and overall survival (OS). These data are consistent with
decreases in VEGF levels observed in cancer patients treated
with repeated low-dose therapy with zoledronic acid.
17 These
results show that N-BPs affect the immune system by both
increasing host antitumor activity and reducing tumor-associated
neovascularization.
BP effects on the bone marrow microenvironment
In MM, bone marrow stromal cells increase the concentration of
angiogenic factors and matrix degrading enzymes in the bone
marrow microenvironment by direct secretion or by the
stimulation of myeloma cells or endocrine cells through
paracrine interactions.
15,16 In-vitro studies have demonstrated
the anticancer potential of zoledronic acid on myeloma cell
lines, but few data are available on its effects on bone marrow
stromal cells.
37 In a study by Corso et al,
37 treatment of bone
marrow stromal cells derived from the bone marrow of myeloma
patients with zoledronic acid reduced proliferation; increased
apoptosis; decreased IL-6, tumor necrosis factor-a and IL-1b
production; and modiﬁed the pattern of expression of adhesion
molecules, especially those involved in plasma cell binding.
These effects on bone marrow stromal cells suggest that the
anticancer activity of zoledronic acid may in part result from its
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Leukemiaability to disrupt the vicious cycle of signaling that promotes
myeloma growth and progression (Figure 1b).
Taken together, the data available suggest that BPs inhibit MM
growth directly (Figure 1a) and indirectly via the bone marrow
microenvironment or by stimulating the immune system
(Figure 1b). The ﬁnal mechanism responsible for a possible
antimyeloma effect is not fully understood, but it seems that
indirect effects via modulation of the microenvironment mediate
a broader antimyeloma effect.
Clinical evidence of the antimyeloma effect of BPs
Data from clinical trials of BPs in patients with MM
38–40
provided the ﬁrst clinical evidence of antimyeloma activity
of BPs. For example, in a long-term follow-up (8.6 years) of a
placebo-controlled trial (N¼619), the subset of clodronate-
treated patients who did not have vertebral fractures at baseline
had signiﬁcantly longer OS vs patients who received placebo
(median OS, 59 months vs 37 months, respectively;
P¼0.006).
40 Similarly, in patients with newly diagnosed or
relapsed/refractory MM (N¼392), long-term treatment with
pamidronate signiﬁcantly increased survival in the subset of
patients with MM receiving second-line antimyeloma therapy
14 months vs 21 months; P¼0.041 compared with placebo.
39
In a retrospective analysis of patients with MM who had bone
marker assessments (N¼353) in a phase III trial comparing
zoledronic acid (4mg) with pamidronate (90mg), patients with
high baseline bone-speciﬁc alkaline phosphatase (X146 IU/l)
levels had signiﬁcantly better 25-month survival with zoledronic
acid than with pamidronate (82 vs 53%, respectively;
P¼0.041).
38
Small clinical studies have also provided insight into the
antimyeloma potential of zoledronic acid. In 2007, Aviles et al
conducted a clinical trial in which 94 patients (treated with
cyclophosphamide, vincristine, melphalan and prednisone)
were randomized to receive either zoledronic acid (4mg
intravenous infusion every 28 days) or not (control group). After
49.6 months median follow-up, assessment of the primary end
points of 5-year event-free survival and 5-year OS showed
signiﬁcantly greater beneﬁt for the zoledronic acid-treated group
vs the control group (5-year event-free survival was 80% in the
zoledronic acid group vs 52% in the control group (Po0.01);
5-year OS was 80% in the zoledronic acid group vs 46% in the
control group (Po0.01)).
41
Recently, the Medical Research Council Myeloma IX trial, a
large, randomized, controlled trial to evaluate the role of BPs
in patients with newly diagnosed MM, was designed and
conducted by the UK Medical Research Council.
42 This phase III
trial (N¼1960) compared the efﬁcacy and safety of monthly
intravenous zoledronic acid (4mg) vs daily oral clodronate
(1600mg) used concurrently with the prevailing standard
treatment. The primary end point of this trial was OS,
and additional end points included progression-free survival,
response rates and incidence of skeletal-related events. Patients
were assigned to two main treatment pathways based on their
age and performance status. Younger, transplant-eligible
patients were assigned to the intensive pathway, which
consisted of induction therapy (randomized between standard
cytotoxic and thalidomide-based regimens) followed by
autologous stem-cell transplantation. Non-transplant eligible
patients were assigned to the non-intensive pathway, which
consisted of systemic therapy only (randomized between
melphalan/prednisone and a thalidomide-based regimen). With-
in each treatment pathway, patients were randomized to oral
clodronate (1600mg/day) or zoledronic acid (4mg via 15min
intravenous infusion) and treated until disease progression
or death.
Of 1960 evaluable patients, 981 received zoledronic acid and
979 received clodronate. At the median follow-up of 3.7 years,
24% and 19% of patients, respectively, discontinued study
before disease progression. Median time on treatment was B1
year across all treatment groups. At the time of the database
lock, 11–13% of patients (zoledronic acid and clodronate arms,
respectively) were still receiving BP treatment. Zoledronic acid
signiﬁcantly prolonged both progression-free survival and OS
(P¼0.0179 and P¼0.0118, respectively) vs clodronate. But it
should be pointed out that the effect of zoledronic acid relative
to clodronate on OS and progression-free survival occurred
in the ﬁrst 4 months, whereas OS and progression-free
survival curves were essentially parallel during follow-up. This
is probably due to the markedly higher relative activity
of zoledronic acid vs clodronate also shown in a rat osteoclast
model.
43 In addition, the better bioavailability of zoledronic
acid due to intravenous application possibly results in a stronger
inhibition of FPPS and subsequent protein prenylation.
44
Zoledronic acid also reduced the proportion of patients with a
skeletal-related event vs clodronate (27.0 vs 35.3%, respec-
tively; P¼0.0004). Further, the improvement in OS was
maintained after adjustment for time to ﬁrst skeletal-related
event in a Cox model (P¼0.0178), suggesting that antimyeloma
effects likely underlie the OS beneﬁt. In addition, zoledronic
acid halved the incidence of new osteolytic lesions, regardless
of treatment pathway.
42 These data support an antimyeloma
beneﬁt from zoledronic acid treatment in patients with newly
diagnosed MM.
In contrast to these studies demonstrating the antimyeloma
beneﬁts of BPs, there are also reports that suggest that BPs do not
have any clinically meaningful effect on the progression of MM.
For example, in an updated indirect meta-analysis of 17 trials
with B3000 patients,
45 the authors concluded that BP treatment
was not signiﬁcantly associated with any survival beneﬁt.
However, it should be noted that this study included several
different BPs, which in individual studies have shown differ-
ences in their antimyeloma activity. Overall, zoledronic acid
and pamidronate have proven to be more effective than other
BPs in terms of the clinical beneﬁt they provide. Moreover,
it should be noted that these analyses did not include the
Medical Research Council Myeloma IX study
42 and that
although it did include the study by Aviles et al
41 that showed
survival beneﬁt, it comprised only a small fraction of the pooled
population and the effect might therefore be masked. Similarly,
in a study by McCloskey et al,
40,46 survival beneﬁt was not
observed in the overall study population, but subgroup
analysis showed signiﬁcant survival beneﬁt in the subset
of patients without skeletal involvement at diagnosis. Finally,
in the study by Musto et al,
47 zoledronic acid treatment did
not have an effect on the progression of asymptomatic
MM to symptomatic disease. Taken together, these data suggest
that to gain clinically meaningful insight into the question
of antimyeloma beneﬁt, one may need to evaluate data not
only in the context of a speciﬁc type of BP but also in the
disease stage.
Discussion
BPs have an important role in the treatment of MM bone
disease. In addition to the established beneﬁt to skeletal health,
there are both in-vitro and in-vivo evidence that BPs have
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Leukemiapotential antimyeloma effects. For example, Tassone et al
29
showed that combination of zoledronic acid and dexamethas-
one inhibits growth and induces apoptotic death synergistically
in MM cell lines. Ural et al
30 extended the observation of
zoledronic acid synergy with antimyeloma agents in their study
demonstrating cytotoxic effects of zoledronic acid in combin-
ation with dexamethasone and thalidomide on myeloma cell
lines ARH-77 (EBV transformed) and RPMI-8226. Croucher
et al
25 used zoledronic acid on 5T2MM-bearing mice, and
results showed that N-BPs decreased osteolysis, tumor burden,
and angiogenesis and increased survival.
Bone resorption in MM releases several types of growth
factors and cytokines including VEGF, tumor necrosis factor and
interleukins; all of which further support the tumor growth. In
addition to the direct effects of BPs on myeloma cells, BPs may
indirectly affect tumor growth by preventing bone resorption
and inhibiting further release of tumor stimulating factors.
Corso et al
37 suggested that BPs inhibit the survival of stromal
cells and block the interaction of plasma and stromal cells, thus
interfering with bone microenvironment. In addition, inhibition
of angiogenesis
17 and immunomodulatory effects of BPs
including activation of Vg9Vd2 T cell-mediated innate immu-
nity
13,35 may contribute to their negative effects on tumor
progression.
The in-vitro evidence of the antimyeloma effects of BPs was
further conﬁrmed by several clinical studies that demonstrate
the efﬁcacy of BPs in reducing skeletal events in patients with
MM with a concomitant antimyeloma effect.
38–42 Aviles et al
41
conducted a trial in 2007 and demonstrated that addition of
zoledronic acid to conventional chemotherapy in treatment-
naive patients improved 5-year event-free survival and 5-year
OS compared with conventional therapy alone. It is of note
that in this trial the event-free survival was high with 80% in the
group treated with zoledronic acid. More recently, the
randomized, controlled Medical Research Council Myeloma
IX study demonstrated that in newly diagnosed patients with
MM, combining conventional therapy with zoledronic
acid provided a signiﬁcant survival advantage compared
with clodronate, across all treatment pathways.
41,42 However,
the response rates within the intensive and non-intensive
chemotherapy arms did not differ with zoledronic acid vs
clodronate treatment, suggesting that the zoledronic acid-
associated OS advantage occurred independently from the
myeloma response. Further, in this trial thalidomide was the
only novel agent used in the intensive or non-intensive cohorts.
Novel agents such as bortezomib
48 and lenalidomide
49 target
MM cells and bone marrow microenvironment cells mediating
bone formation and resorption. Therefore, it is not surprising that
antiresorptive agents that primarily target the bone (that is, BPs
such as zoledronic acid and pamidronate) may also favorably
impact MM.
Future trials need to incorporate novel agents to determine
their optimal use as both antimyeloma therapy and their
synergy with BPs in terms of controlling bone disease.
41,42
Ongoing studies such as DAZZLE (N¼53) and a larger single-
arm trial in Australia (MM6; N¼243) are evaluating the effect
of zoledronic acid on disease progression in patients with
MM. Data from these studies may provide additional clinical
insights into the therapeutic role of zoledronic acid in patients
with MM.
Although other studies
45–47 suggest that BPs do not improve
mortality in the overall study population after treatment with BP,
the majority of data presented herein provides evidence for the
antimyeloma effects of BPs. Further, several studies have proven
the reduction of skeletal-related events in MM patients treated
with either pamidronate or zoledronic acid.
50 Nevertheless,
based on the fact that BPs increase the risk of osteonecrosis of
jaw and are possibly associated with increased risk of atypical
subtrochanteric fractures,
51 the use of BPs needs to be critically
evaluated in the context of the clinical situation of each
individual patient. Although the optimal duration of BP treatment
in this patient population is unknown, the potential antimyeloma
beneﬁt warrants further evaluation of the risk: beneﬁt ratio of BPs
in conjunction with primary treatment for MM. Thus, further
clinical studies that assess the efﬁcacy of BPs in combination with
the prevailing standards of care are warranted.
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